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Gold nanoparticles are elective candidate for cancer therapy. Current efforts are
devoted to developing innovative methods for their synthesis. Besides, understanding
their interaction with cells have become increasingly important for their clinical
application. This work aims to describe a simple approach for the synthesis of extra-
small gold nanoparticles for breast cancer therapy. In brief, a biocompatible and
biodegradable polyamidoamine (named AGMA1-SH), bearing 20%, on a molar basis,
thiol-functionalized repeat units, is employed to stabilize and coat extra-small gold
nanospheres of different sizes (2.5, 3.5, and 5 nm in gold core), and to generate
a nanoplatform for the link with Trastuzumab monoclonal antibody for HER2-positive
breast cancer targeting. Dynamic light scattering, transmission electron microscopy,
ultraviolet visible spectroscopy, X-ray powder diffraction, circular dichroism, protein
quantification assays are used for the characterization. The targeting properties of the
nanosystems are explored to achieve enhanced and selective uptake of AGMA1-SH-
gold nanoparticles by in vitro studies against HER-2 overexpressing cells, SKBR-3 and
compared to HER-2 low expressing cells, MCF-7, and normal fibroblast cell line, NIH-
3T3. In vitro physicochemical characterization demonstrates that gold nanoparticles
modified with AGMA1-SH are more stable in aqueous solution than the unmodified
ones. Additionally, the greater gold nanoparticles size (5-nm) is associated with a
higher stability and conjugation efficiency with Trastuzumab, which retains its folding
and anticancer activity after the conjugation. In particular, the larger Trastuzumab
functionalized nanoparticles displays the highest efficacy (via the pro-apoptotic
protein increase, anti-apoptotic components decrease, survival-proliferation pathways
downregulation) and internalization (via the activation of the classical clathrin-mediated
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endocytosis) in HER-2 overexpressing SKBR-3 cells, without eliciting significant effects
on the other cell lines. The use of biocompatible AGMA1-SH for producing covalently
stabilized gold nanoparticles to achieve selective targeting, cytotoxicity and uptake is
completely novel, offering an important advancement for developing new anticancer
conjugated-gold nanoparticles.
Keywords: cancer cell targeting, polyamidoamines, Trastuzumab, gold nanoparticles, breast cancer
nanomedicine
INTRODUCTION
Breast cancer is the most frequent and invasive cancer type
in women (Rojas and Stuckey, 2016). There is an increasing
demand for novel, efficient and specific diagnostic and medical
tools to face the adverse side-effects of the traditional ones.
Some invasive forms of breast cancer (i.e. locally advanced
breast cancer) presented a twofold higher incidence than the
others, suggesting an urgent improvement of Trastuzumab
(HerceptinTM) delivery toward erbB2 tyrosine kinase receptor
(HER-2) found overexpressed in ∼25%–30% of breast cancers
(Sawaki et al., 2006). Engineered delivery systems based on gold
nanoparticles (AuNPs) are particularly promising to address this
problem. AuNP formulations are employed for a wide range
of medical applications, including contrast and photothermal
agents for computed tomography (CT) and tumor photothermal
ablation, respectively (Mieszawska et al., 2013). Their chemical
and physical properties, that span the broader visible to near-
infrared, ensure them features such as low toxicity, high stability,
easy synthesis and conjugation with cancer-specific biomolecules
(Lee et al., 2014; Carnovale et al., 2016). It is generally agreed
that physicochemical differences in nanoparticles such as particle
size, shape, surface charge and surface coating could vary the
way particles are recognized, processed and excreted by the body
(Carnovale et al., 2016). Notably, the molecular rules governing
these properties are poorly understood, and the different set-
up conditions used in the different laboratories (such as cell
types, dosage schedule, measurement methods) make it difficult
to drawing valid and conclusive information. Experimental and
theoretical studies stated that the optimal size for AuNPs cellular
uptake ranges from 25 to 50 nm, since it stimulates efficiently
membrane wrapping and receptor-ligand interaction to drive
the NPs into the cell (Gao et al., 2005; Jiang et al., 2008;
Dreaden et al., 2012; Panariti et al., 2012; Saw et al., 2018).
Surface charge can also have an effect on the cellular uptake
(Zhang et al., 2015). Interacting with negative cell membranes,
the electropositive nanoparticles exhibited a higher cellular
uptake efficiency compared to electronegative ones. Conjugation
of AuNPs with targeting molecules effectively improves the
tumor target delivery (Paciotti et al., 2004). Several studies
reported that Trastuzumab could be successfully immobilized
on gold nanoparticles to improve their interactions with SKBR3
breast cancer cells, overcome Trastuzumab resistance and detect
breast cancer (Hainfeld et al., 2006; Bickford et al., 2008;
Chattopadhyay et al., 2010; Carpin et al., 2011; Lee et al., 2014).
In vitro experiments indicated that, while human skin cells
proliferated in the presence of Trastuzumab-conjugated gold
nanoparticles, most of the breast cancer cells died (Rathinaraj
et al., 2015). Despite the broad interest surrounding gold-based
nanosystems, reproducibility, toxicity and excretion concerns
limit their clinical translations (Choi et al., 2007; Lewinski
et al., 2008; Tam et al., 2010). Indeed, currently no gold
nanoparticles have yet been approved by the FDA agency.
Different biodegradable polymers were tested for assembling
and coating gold nanoparticles clusters (Tam et al., 2010), while
minimizing immunogenicity reactions. Cheheltani et al. (2016)
proposed a small, excretable AuNP-based platform, encapsulated
into biodegradable poly di(carboxylatophenoxy)phosphazene
(PCPP) nanospheres. A study by Tam et al. (2010) reported
polymer/inorganic nanoclusters combining the imaging contrast
and therapeutic capabilities with the biodegradability of a
polymer stabilizer. Linear polyamidoamines (PAAs) have recently
emerged as promising tools for drug delivery as they offer key
advantages due to their ease of formulation and biodegradability
(Ferruti et al., 2005; Jacchetti et al., 2008; Ferruti, 2013; Mauro
et al., 2013). PAAs were previously investigated as anticancer
drug carriers (Lavignac et al., 2009). In particular, the PAA
nicknamed AGMA1 can be used as a potential non-viral,
non-toxic and efficient vector for the intracellular delivery of
siRNA and DNA (Cavalli et al., 2010; Cavalli et al., 2017).
Interestingly, AGMA1, containing tert-amine, carboxyl and
guanidine groups, whose repeat unit is reminiscent of the arg-
gly-asp (RGD) peptide motif (Franchini et al., 2006), a well-
known fibronectin sequence mediating cell attachment, can
act as an excellent cell adhesion and proliferation substrate
(Gualandi et al., 2016). For in vivo applications, gold-based
nanosystems should be larger than 6 nm in diameter to ensure
long blood circulation, hence accumulation in diseased tissues
but slowly breaking down into sub-6 nm components for rapidly
excretion via the kidneys (Arruebo et al., 2007; Choi et al.,
2007). The goal of the present study was to develop more
efficient gold nanoparticles for therapeutic use. To this purpose, a
biocompatible and biodegradable polyamidoamine bearing 20%,
on a molar basis, randomly distributed SH pendants (AGMA1-
SH, indicated also as “P”) was employed to stabilize AuNPs of
different sizes, that is 2.5, 3.5, and 5 nm in Au core (Au@P),
decorated with Trastuzumab (Au@PT), whose hydrodynamic
diameter was suitable for a cellular uptake (Figure 1). AGMA1,
besides being a biocompatible and biodegradable polymer,
was found to be easily internalized in cells and, therefore,
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FIGURE 1 | Schematic representation of AuNPs coated with AGMA1-SH and Trastuzumab.
it can be expected to facilitate the AuNPs cellular uptake
(Franchini et al., 2006; Cavalli et al., 2010), whereas thiol groups
are supposed to stabilize the AGMA1-gold bond by the renowned
S-Au soft-soft interaction. Once tested in vivo, it is reasonable
to speculate that, because of the AGMA1 biodegradability, the
small Au core component (ranging from 2.5 to 5 nm) may be the
only one to be extruded by the urinary system. In this work, the
impact size of Au@P nanoparticles on the interactions with both
breast cancer cells, and healthy cells was systemically studied.
The cytotoxicity and cellular uptake of all nanoparticles were
studied by MTT and ICP-MS tests. Western blot analysis and
cellular uptake studies by means of specific endocytosis inhibitors
were further carried out to explore the interaction with and
mechanism of internalization of Au@PT by SKBR-3 target cells.
MATERIALS AND METHODS
Reagents
4-Aminobutylguanidine sulfate (97%), lithium hydroxide
monohydrate (99%), cystamine hydrochloride (96%), 2-
mercaptoethanol (99%) and calcium chloride (97%) were
purchased from Sigma-Aldrich and used as provided. 2,2-
Bis(acrylamido)acetic acid (96%) was synthesized as previously
described (Ferruti et al., 1999). HAuCl4 solution (composition:
17 wt.% Au; concentration: 30 wt.% in dilute HCl) was purchased
from Sigma-Aldrich and diluted with water to achieve a final Au
concentration of 10 mg/mL. NaBH4 (>96% pure), purchased
from Sigma-Aldrich, was employed as the reducing agent
for Au3+ to colloidal gold dispersion (10 mg/mL). Activated
carbon Vulcan XC72R (specific area = 254 m2 g−1, pore
volume = 0.19 mL g−1) from CABOT was used as a supporting
material for colloidal samples for XRPD analysis. MilliQ
water obtained by an Academic A-10 Millipore apparatus was
employed as a solvent for all aqueous solutions. Trastuzumab
(Herceptin R©, Roche) was kindly provided by the Chemotherapic
section of Policlinico San Matteo (Pavia). For Western blot
analyses, primary mouse monoclonal anti β-actin was purchased
from Santa Cruz Biotechnology, mouse monoclonal anti-ERK1/2
and rabbit polyclonal anti-phospho ERK1/2 (Thr 202/204) from
Abcam, rabbit monoclonal anti-AKT and rabbit polyclonal
anti-phospho -AKT (Ser 473) from Cell Signaling Technologies
(Danvers, MA, United States) and rabbit monoclonal anti-BAX
and anti-BCL-XL from Thermo Fisher Scientific. Horseradish
peroxidase (HRP)-conjugated secondary antibodies anti-mouse
and anti-rabbit (Dako) anti-human (Tebu-bio) were used,
and detection was performed by enhanced chemiluminescent
substrate (ECL) solutions (Pierce Thermo Fisher Scientific,
Rockford, IL, United States).
Instruments
1H and 13C NMR spectra were run on a Brüker Advance 400
spectrometer operating at 400.132 (1H) and 100.623 (13C) MHz.
Size exclusion chromatography (SEC) traces were obtained with
a Knauer Pump 1000 equipped with a Knauer Autosampler 3800,
TSKgel G4000 PW and G3000 PW TosoHaas columns connected
in series, Light Scattering (LS) Viscotek 270 Dual Detector, UV
detector Waters model 486, operating at 230 nm, and a refractive
index detector Waters model 2410. The mobile phase was a 0.1
M Tris buffer pH 8.00 (0.05 M with 0.2 M sodium chloride
(Bignotti et al., 1994). The operational conditions were: sample
concentration 20 mg/mL; flow rate 1 µL/min; injection volume
20 µL; column dimensions 300 × 7.5 mm2, temperature 25◦C.
The instrument constants were determined using PEO 19 kDa as
a narrow polymer standard. All samples were filtered through a
0.2 µm syringe Whatman filter before measurements.
Synthesis of AGMA1-SH
2,2-Bis(acrylamido)acetic acid (4.128 g, 20.0 mmol) and lithium
hydroxide monohydrate (1.53 g, 36.0 mmol) were dissolved in
water (18 mL) and 4-aminobutylguanidine (agmatine) sulfate
(3.765 g, 16.0 mmol) was added under vigorous stirring. The
reaction mixture was heated up to 40◦C until dissolution and
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kept under nitrogen atmosphere at room temperature with
gentle stirring for 1 day (d). After this time, the reaction
mixture was cooled down to room temperature and cystamine
dihydrochloride (0.469 g, 2.0 mmol) and lithium hydroxide
monohydrate (0.170 g, 4 mmol) were added. The resultant
mixture was kept at room temperature for 10 days until a
soft transparent hydrogel was obtained. Then water (40 mL)
and excess mercaptoethanol (8.0 mL) were added until a clear
solution was obtained. This was diluted with water (100 mL),
acidified to pH 4.5 with 37% hydrochloric acid and then
ultrafiltered through a membrane with nominal molecular weight
cut-off 3000. The final product was retrieved by freeze-drying the
retained fraction. Yield 68%, M¯n = 8400, PDI = 1.25.
1H NMR (D2O): δ (ppm) = 1.52–1.60 (br, NCH2CH2CH2);
1.71–1.77 (br, NCH2CH2); 2.64–2.76 (br, NHCOCH2); 2.92–
2.94 (m, CH2S); 3.08–3.20 (m, NCOCH2CH2N); 3.34–3.47 (br,
NCH2CH2CH2 and NCH2CH2S); 5.51–5.56 (s, CHCOOH).
13C NMR (D2O): d (ppm) = 18.5 (CH2S); 22.3 (NCH2
CH2CH2); 25.0 (NCH2CH2); 29.0 (NHCOCH2); 40.4 (CH2
CH2NH); 49.1 (NCH2CH2CONH); 52.5 (NCH2CH2CH2CH2
NH); 54.8 (NCH2CH2S); 56.0 (CHCOOH); 155.1 (H2NC = NH);
171.3 (NHCO); 173.5 (COOH).
Synthesis of Gold Nanoparticles
Decorated With AGMA1-SH and
Trastuzumab
Three differently sized colloidal samples of AGMA1-SH-coated
gold nanoparticles decorated with Trastuzumab (Herceptin R©),
were prepared by varying gold solution concentration from
20 ppm to 400 ppm. The samples were labeled as 2.5Au@PT,
3.5Au@PT, and 5Au@PT, where the number indicates the average
diameter of gold core (2.5, 3.5, and 5.0 nm, respectively),
P means the polymer (AGMA1-SH) and T the antibody
drug (Trastuzumab). Accordingly, the following parameters
were optimized to produce stable colloidal nanosystems over
time: gold solution concentration (20 ppm for 2.5Au@PT,
200 ppm for 3.5Au@PT, and 400 ppm for 5Au@PT), AGMA1-
SH:Au:Trastuzumab ratio (1wt.:1wt.:1wt.) and NaBH4:Au ratio
(1wt.:1wt.). More in detail, proper aliquots of AGMA1-SH
aqueous solution (10 mg/mL) were added under stirring to
defined volumes of HAuCl4 aqueous solution (10 mg/mL Au)
and MilliQ R© water at room temperature. Established amounts
of freshly prepared NaBH4 aqueous solution (10 mg/mL)
were rapidly added under vigorous stirring to reduce Au3+
to Au0 and, hence, produce light-tea to reddish colored
colloidal dispersions. Finally, proper volumes of Trastuzumab
aqueous solution (20 mg/mL) were poured drop wise. Only
in the case of the 5Au@PT sample, sodium borohydride
was added prior to the polymer in order to allow gold
nanoparticles to grow up to 5.0 nm. Supplementary Table S1
reports the established aliquots for each component. At
the end of reaction, to remove the excess of synthesis
reagents or/and to eliminate unbound antibody, each AuNPs
solution was purified by dialysis for 24 h in a Float-A-Lyzer
Spectra/Por G2 (MWCO of 100 kDa for Au@PT) under
stirring at 4◦C.
Synthesis of Gold Nanoparticles
Decorated With AGMA1-SH or
Trastuzumab
Three differently sized AuNP@AGMA1-SH colloidal samples
without the drug (Trastuzumab) and three differently
sized AuNP@Trastuzumab colloidal samples without the
polymer (AGMA1-SH) were synthesized adopting the
aforementioned procedure. The following parameters were
optimized in order to produce stable colloidal nanosystems:
gold solution concentration (20 – 400 ppm), AGMA1-
SH:Au or Trastuzumab:Au ratios (1wt.:1wt.) and NaBH4:Au
ratio (1wt.:1wt.). The samples were labeled as 2.5Au@P,
3.5Au@P, 5Au@P and 2.5Au@T, 3.5Au@T, 5Au@T respectively.
Supplementary Table S1 reports the established aliquots for
each component. At the end of reaction, to remove the excess
of synthesis reagents each AuNPs solution was purified by
dialysis for 24 hours (h) in a Float-A-Lyzer Spectra/Por G2
(MWCO 10 kDa for Au@P and 100 kDa for Au@T, respectively)
under stirring at 4◦C. As evinced by microscopic analyses
(TEM), AuNPs were synthesized in uniform spherical sizes.
Hence, by using the simple geometrical model of spherical
particles (Eq. 1–6), the theoretical Trastuzumab molecule to
gold nanoparticle ratio (T/AuNP) could be determined for the
three differently sized nanosystems. Accordingly, T/AuNP = 0.65
for ‘2.5Au’ samples, 1.79 for ‘3.5Au’ samples and 5.21 for
‘5Au’ samples. In addition, extrapolating the fraction of gold
atoms lying at the surface (gold dispersion from Supplementary
Figure S1) led to the theoretical Trastuzumab molecule to
gold surface atom ratio (T/surface Au) for the three differently
sized samples:
T/surface Au = 0.0025 for ‘2.5Au’ samples, 0.0039 for ‘3.5Au’
samples and 0.0054 for ‘5Au’ samples.
volume AuNP = 4
3
pir3 (r is Au nanoparticle radius = 1.25,
1.75, and 2.5 nm respectively) (1)
mass AuNP = volume AuNP × ρ
(ρis Au density = 19.3 g/cm3) (2)
number AuNP = mass Au in the sample
mass AuNP
(3)
moles AuNP = mass AuNP/atomic weight Au (4)
atoms AuNP = moles AuNP × Avogadro′s number (5)
surface atoms AuNP = gold dispersion (%)× atoms AuNP
(Gold dispersion is 55% for ‘2.5Au’, 35%
for ‘3.5Au’ and 25% for ‘5Au’) (6)
Physicochemical Characterization
Dynamic light scattering (DLS) and Z-potential analyses were
carried out on 1 mg/mL nanoparticle aqueous suspensions
prepared using MilliQ water, with a Malvern Zetasizer NanoZS
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instrument equipped with a laser fitted at 532 nm and fixed
173◦ scattering angle. Before analyses, samples were filtered
through a 0.2 µm syringe Whatman filter. The solution pH was
adjusted to the selected value, using 0.1 M HCl or 0.1 M NaOH
aqueous solutions. Measurements were performed in triplicate,
and the reported values averaged over of 10 runs. Regarding
DLS measurements on AGMA1-SH-coated gold nanoparticles
decorated with Trastuzumab (Au@PT), AGMA1-SH-coated
gold nanoparticles (Au@P) and Trastuzumab-coated gold
nanoparticles (Au@Trastuzumab), 20 mg/L aqueous suspensions
were analyzed. X-ray powder diffraction (XRPD) analyses were
performed employing a Rigaku D III-MAX horizontal-scan
powder diffractometer with Cu Kα radiation (λ = 1.5418 Å) to
determine the average size of gold crystallites using the Scherrer
equation (Patterson, 1939). The Bragg angle was rotated in the
34◦– 43◦ 2θ interval and the mean diameter d of gold core
was determined considering the peak at 2θ = 38.5◦, typical of
metallic gold. All the colloidal samples were immobilized on
XC72R carbon to obtain the theoretical amount of 1% Au. UV-
vis spectra were collected in the 200–800 nm region using a
HP 8453 diode array instrument on colloidal samples (20 ppm
Au) for determining the plasmon resonance band (PRB) of
gold nanoparticles detected near 500–530 nm in the 2–10-nm-
diameter range.
Transmission Electron Microscopy
TEM analysis was performed by using a JEOL JEM 3010
operating at a 300-kV acceleration voltage. Briefly, 10 µL of
each type of gold nanoparticle suspension in water (20 µg/mL)
deposed on ParlodionTM membranes.
Efficiency of Trastuzumab Conjugation
The efficiency of Trastuzumab conjugation to nanoparticles was
assessed by indirect (Bicinchoninic Acid, BCA), and direct (dot-
blot) approaches as previously described (Liu et al., 2010; Zhou
et al., 2015; Di Francesco et al., 2018; Codullo et al., 2019).
In short, both Au@PT and Au@T nanoparticles suspensions
(20 µg/mL) were centrifuged at 3000 × g for 15 min, then
the supernatants were collected for determine the unbound
Trastuzumab concentration by BCA assay (Pierce Biotechnology
Inc., Rockford, IL, United States), while the pellets were re-
suspended in 1 mL of MilliQ water for dot blot assay.
BCA Assay
The unbound content in the resulting solution was determined by
BCA assay according to the specifications of the manufacturer.
The unbound amounts were calculated from properly drawn
Trastuzumab calibration curve. Trastuzumab amount conjugated
to nanoparticles was thus obtained via reduction of the amount
in the supernatant from the initial amount. The percentage of
conjugation efficiency (CE) was calculated as follows (Martínez-
Jothar et al., 2019):
% CE = (total amount of T added-unbound T)
total amount of T added
∗ 100
Dot Blot Assay
Different amounts of Trastuzumab-functionalized Au@P
differently sized were spotted on nitrocellulose membrane
Amersham Hybond ECL, GE Healthcare Life Sciences,
Pittsburgh, PA, United States) and air-dried. 2.5Au@P, 3.5Au@P,
5Au@P as negative controls. In parallel, Au@T samples dot
blot was also performed. The non-specific sites were blocked
by soaking the membrane in 5% BSA in TBS containing 0.05%
Tween 20 for 1 h at room temperature (RT). The membrane was
then incubated using goat anti-human-HRP-conjugated antibody
(1:1000) for 1 h at RT and after extensive washing developed
with enhanced chemiluminescence reagents (LI-COR) and
ImageQuant LAS4000 Imaging System (Ge Healthcare). The
spots were then analyzed with ImageQuant TL software (Ge
Healthcare) and the results were normalized to calibration curve
containing known amounts of Trastuzumab.
Circular Dichroism
The secondary structure of the Trastuzumab free (20 µg/mL)
and Trastuzumab-conjugated gold nanoparticles (20 µg/mL)
were evaluated with circular dichroism (CD). CD spectra were
measured using Jasco J710 spectropolarimeter (Jasco Corp.,
Tokyo, Japan) at 25◦C and in a 1 cm path-length quartz cell under
the following conditions: 300–190 nm spectral range, 2 nm of
bandwidth, 200 nm min-1 of scan speed and 3 accumulation.
Data was processed using 10-point smoothing in Origin 6.0
(OriginLab Corporation, Northampton, MA, United States).
In vitro Trastuzumab Release From Gold
Nanoparticles Decorated With
AGMA1-SH
2.5Au@PT, 3.5Au@PT, and 5Au@PT (20 µg) were suspended
in 1 mL of MilliQ water, in a low-protein binding centrifuge
tube, and kept at room temperature. At select time points (1 –
15 days), each type of nanoparticles suspension was centrifuged,
the supernatant was collected and replaced with the same
volume of fresh release medium (Colzani et al., 2018). The
concentration of antibody in the supernatants was determined
using the BCA Kit as described above. Standard curve of
Trastuzumab was used to determine antibody concentrations
in each sample. The results are expressed as the percentage of
cumulative fraction of Trastuzumab released at each time point
compared to the conjugated amount. The in vitro release of
2.5Au@T, 3.5Au@T, and 5Au@T was not analyzed due to the
higher aggregation recorded immediately within the first days
after their synthesis.
Cell Types and Culture Conditions
HER2 positive breast adenocarcinoma cells (SKBR-3), ERα
positive breast adenocarcinoma cells (MCF-7) used as cancer
negative control, murine fibroblasts cells (NIH-3T3) used
as negative control. All cell lines were obtained from the
American Type Culture Collection (HTB85, ATCC, Manassas,
VA, United States). After thawing, SKBR-3 cell line was cultured
in McCoy’s 5A Medium Modified (Sigma-Aldrich), 10% of
Fetal Bovine Serum (FBS, EuroClone), 1% of L-Glutamine
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(Lonza), 2% sodium pyruvate (Lonza), 0.4% antibiotics
(Lonza) and 0.1% fungizone. MCF-7 cell line was cultured
in Minimum Essential Medium Eagle (Sigma-Aldrich), 10%
of Fetal Bovine Serum (EuroClone), 1% sodium pyruvate
(Lonza), 1% Non-Essential Aminoacids (EuroClone), 1%
Bovine Insulin (Sigma-Aldrich), 1% L-Glutamine (Lonza) and
0.4% antibiotics (Lonza). NIH-3T3 cell line was cultured in
Dulbecco’s Modified Eagle Medium High Glucose 4.5 mg/mL
(Sigma-Aldrich), 10% of Bovine Calf Serum (BCS, EuroClone)
and 1% of L-Glutamine (Lonza). All cell lines were incubated
at 37◦C in 5% CO2, routinely trypsinized (Trypsin EDTA
solution 1X, Lonza) after confluence, counted and seeded
into wells.
Stability of AuNPs Upon Incubation With
Cell Culture Media by Dynamic Light
Scattering
Prior to all biological investigations, each suspension of AGMA1-
SH-coated gold nanoparticles decorated with Trastuzumab
(2 µg/mL) was centrifuged and resuspended in the cell culture
media appropriate for the corresponding cell line, containing
10% of serum, and incubated at physiological temperature
(37◦C), without shaking, to mimic cell culture conditions
(Halamoda-Kenzaoui et al., 2015; Maris¸ca and Leopold, 2019).
Size change was tracked by serial DLS size measurements at
0 (directly after dispersion in the complex media) and after
4 h of incubation.
Cell Viability
Cells were seeded at 1 × 104 viable cells/well on 96-well plates
and incubated for 24 h (to allow cells to attach to the well).
After the culture medium removal, cells were incubated with
media containing increasing concentration of each types of
gold nanoparticles. At fixed incubation times, the quantitative
3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide
(MTT, Sigma Aldrich, St. Louis, MO, United States) assay
was performed to assess the dehydrogenase activity, as an
indicator of the metabolic state of cells, as previously described
(Merli et al., 2018). The cell viability was expressed as
percentage related to the control (untreated) set equal to
100%. At day 3 of incubation, a qualitative viability assay
[fluorescein diacetate (FDA) assay] was performed on SKBR-
3 untreated (ctrl), treated with T free (2 µg/mL), 2.5Au@PT
(2 µg/mL) and 5Au@PT (2 µg/mL), as previously described
(Bloise et al., 2013).
Scanning Electron Microscopy (SEM)
For morphological evaluation all types of cells were seeded
on plastic cell culture coverslip disks (Thermanox Plastic,
Nalge Nunc International, Rochester, NY, United States), then
incubated or not with nanoparticles suspensions (2 µg/mL)
and treated as previously described (Bloise et al., 2013). Before
observation, samples were sputter coated with gold and observed
using a Field Emission Scanning Electron Microscope (FESEM
Supra 25, Zeiss).
Uptake Studies by Inductively Coupled
Plasma Mass Spectrometry (ICP-MS)
All types of cell lines were plated (500000/well) on a 6-well
plate and treated for 1 and 3 days with 2 µg/mL of each
types of nanoparticles (2 mL volume added in each well). After
treatments, cells were washed three times with PBS to eliminate
the NPs which were not internalized in cells, trypsinized, counted
and centrifuged in order to obtain the cellular pellet. The cellular
pellet was treated with 1X RIPA buffer (diluting the 10X RIPA in
sterile distilled water, EDM Millipore Corporation, Chemicon) in
ice for 30 min, transferred in sterile Eppendorf and centrifuged
at 13000 rpm for 15 min at 4◦C. The pellet was separated from
the supernatant and treated with 750 µL of freshly prepared aqua
regia. The samples were diluted to 3 mL with bidistilled water
and analyzed for the Au content with ICP-MS (ELAN DRC,
Perkin Elmer). The nanoparticles uptake efficiency per cell was
calculated as previously described (Gunduz et al., 2017): Uptake
efficiency (%) = (Number of NPs taken up by cells/Number of NPs
incubated with cells) ∗ 100%. To obtain number of AuNP in each
sample, total ppm determined by ICP-MS was divided to the
mass of one AuNP. Total AuNPs number was divided to cells
number as follow: number of AuNPs/n◦ of cells = (total mass
of AuNPs by ICP-MS/mass of one AuNP)/n◦ of cells (where the
mass of one AuNP = ρ 4/3 ρ3pi with ρ = density of gold; r = radius
of one AuNP).
Confocal Laser Scanning Microscopy
(CLSM)
SKBR-3, cells were seeded on cover glasses with a density of
50.000 cells in a 24 well culture plate. After 24 h incubation,
cells were treated with Trastuzumab free (2 µg/mL), 2.5Au@PT,
5Au@PT nanoparticles (2 µg/mL) and without any control
for 24 h. Untreated cells were used as control. At the end of
the culture time, the cells were washed with PBS, fixed with
4% (w/v) paraformaldehyde solution for 15 min, permeabilized
with 0.1% Triton X-100, and blocked with Bovine Serum
Albumin (BSA 3% in 1X PBS) for 1 hour at room temperature.
Finally, cells were incubated with Alexa-Fluor-488–conjugated
secondary antibodies anti-human (diluted 1:1000) for 45 min
at room temperature (Invitrogen; excitation/emission maxima
∼ 495/519 nm). At the end of the incubation, the cells were
washed in PBS, counterstained with a solution of Hoechst
33342 (2 µg/mL in 1X PBS; excitation/emission maxima
∼361/497 nm) to target the cellular nuclei, and then washed.
Finally, samples were observed with a confocal fluorescence
microscope (Leica TCS SPII Microsystems, Wetzlar, Germany).
The AuNPs were visualized in reflection bands after the
excitation at 545 nm.
Ultrastructural Analysis
For the ultrastructural analysis, cells underwent a Silver
enhancement made with Silver Enhancer Kit (Sigma-Aldrich)
in order to increase the signal of colloidal gold particles.
Subsequently, cells were fixed with 2.5% glutaraldehyde in PBS
and a post-fixation with 1% osmium tetroxide in dH2O was
performed to fix lipids. The samples were gradually dehydrated in
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acetone and embedded in epoxy resin. Thin sections of 70–80 nm
were obtained with Reichert OM3 ultramicrotome and placed on
formvar-carbon-coated nickel grids (300 Mesh). Finally, the grids
were stained with uranyl and lead, using an unstained grid as
control. All the samples were observed on a Zeiss EM900 electron
microscope operating at 80 kV.
Endocytosis Pathway Determination
Cells were seeded in 6-well culture plates at a density of
500000 cells/well, after 24 h incubated with different endocytosis
inhibitors [2.5 mM amiloride (Sigma-Aldrich), 2.5 µg/mL
chlorpromazine (Sigma-Aldrich) and 100 µM indomethacin
(Sigma-Aldrich)] and then maintained for 1 h at 37◦C with 5%
of CO2-air. The concentrations and treatment times of each
chemical inhibitors were optimized in a preliminary experiment
to select the maximum non-toxic doses and treatment times.
After 1 h incubation, the inhibitors were removed, and the
cells exposed to 2 µg/mL AuNPs in complete medium for 24 h
incubation. Then ICP-MS protocol was followed as described in
the previous section.
Western Blot Analysis
Cells were scraped from all the samples, including T, and lysed
with ice-cold lysis buffer (1X RIPA buffer containing 1 mM and
1X protease inhibitor (Protease Inhibitor Tablets, SIGMA) for
30 min on ice. The lysates were then used for western blot analysis
according literature protocol (Cristofaro et al., 2018). Primary
antibodies anti-phosphorylated AKT and anti-AKT (diluted
1:500), anti-ERK and anti-phosphorylated ERK (diluted 1:1000),
anti-BAX and anti-BCL-XL (diluted 1:500), anti-β-actin (diluted
1:500) and appropriate secondary antibodies HRP-conjugated
were used. Detection was performed as described in the dot-
blot section. Bands densitometry analysis was carried out with
Image J software.
Statistical Analysis
All statistical calculations were carried out using GraphPad
Prism 5.0 (GraphPad Inc., San Diego, CA, United States).
Statistical analysis was performed using Student’s unpaired t-test
and through one-way variance analysis (ANOVA), followed by
Bonferroni post hoc, for multiple comparisons (significance level
of p ≤ 0.05).
RESULTS AND DISCUSSION
Synthesis of AGMA1-SH
AGMA1-SH bearing 20% randomly distributed thiol-
functionalized repeat units was synthesized following a
two-step procedure previously reported for obtaining thiol-
functionalized ISA23 (a cytobiocompatible, stealth-like PAA
deriving from the polyaddition of 2,2-bisacrylamidoacetic acid
with 2-methylpiperazine) (Donghi et al., 2009). According to
this procedure (Figure 2), at 20% on a molar basis, cysteamine-
deriving units were introduced in AGMA1 by substituting in the
preparation recipe 10% cystamine for 20% agmatine. Cystamine,
being a tetrafunctional monomer in Michael-type polyaddition
acted as a crosslinker, and a soft hydrogel was obtained.
Cystamine disulfide groups were subsequently reductively
cleaved with excess 2-mercaptoethanol. The major portion
of AGMA1-SH repeat units still bore 4-aminobutylguanidine
pendants, as AGMA1, therefore it maintained its favorable
cell-adhesive properties, but also contained cysteamine moieties
capable of ensuring strong interactions with gold.
Synthesis of Gold Nanoparticles
Decorated With AGMA1-SH and/or
Trastuzumab
Three differently sized AGMA1-SH-coated AuNPs decorated
with Trastuzumab were synthesized according to a previously
established green and robust route (Comotti et al., 2004).
The aim was to assess how variously sized nanosystems could
affect the biological activity, in particular endocytosis and
apoptosis. In order to evaluate the role of each component
inside the nanosystem, three differently sized AGMA1-SH-
coated AuNPs and Trastuzumab-coated AuNPs were also
prepared for comparison. Tuning gold nanoparticles diameter
was expected to change anti-cancer ability of the nanosystem
as a consequence of different surface to volume ratios which
might affect the gold interaction with the polymer and drug,
as well as their surroundings. On this regard, Bond and
Thompson published a plot able to determine gold dispersion
per nanoparticle (percentage of surface gold atoms with respect
to gold atoms per nanoparticle) as a function of nanoparticle
diameter (Bond and Thompson, 1999). Surface area and
gold atoms number versus diameter can be determined as
well (Supplementary Figure S1). Accordingly, the smaller the
particles, the higher the fraction of atoms on the surface thus
more gold sites are available for interaction. In particular, the
three tailored AuNPs sizes (2.5, 3.5, and 5 nm) would lead
to marked different gold dispersions of around 55, 35, and
25%, respectively. All the nanosystems were stable over time
due to the mentioned Au-S soft-soft interaction, since sulfur
is present either in AGMA1-SH or Trastuzumab (Della Pina
et al., 2009). Briefly, the AuNP core (produced by chloroauric
acid reduction, see below) was coated with the biocompatible
polymer AGMA1-SH in order to prevent the nanosystem either
from aggregation or ingestion by phagocytes (‘stealth effect’).
The subsequent conjugation to an anticancer molecule (the
antibody drug Trastuzumab) would enable gold nanovectors
to recognize and inhibit only tumor cells. HAuCl4 aqueous
solution served as a gold source, whose concentration was
tuned to achieve the desired size of AuNPs and, hence, of
the whole nanosystem. Proper amounts of AGMA1-SH were
then added and Au3+ was instantly reduced to Au0 by NaBH4
addition without the presence of any conventional stabilizer
(namely PVA, PVP or sodium citrate, often cytotoxic) due to
the intrinsic protecting effect of the polymer. Shortly after, the
polymer-coated AuNPs were decorated with the drug. Only
in the case of 5Au@PT, 5Au@P, and 5Au@T samples, sodium
borohydride was added prior to the polymer or antibody drug
addition in order to allow gold nanoparticles to grow up to
5.0 nm. Both the polymer and the drug, in fact, were found
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FIGURE 2 | Synthesis of AGMA1-SH.
to hinder gold nanoparticles growth when present before the
reducing agent addition, probably due to their inhibiting effect
against aggregation (Figure 1). More importantly, the innovative
protocol introduces some advantages with respect to other
synthetic routes commonly adopted (Rossi et al., 2016). First,
the use of thiol-functionalized biocompatible PAAs allows to
avoid conventional stabilizers, often cytotoxic, via Au-S bonds,
which ensure long-term stability of the nanosystem without
cytotoxicity. Second, the use of an instant reducing reagent
(NaBH4), whose excess can be easily removed by dialysis, leads
to homogeneously sized nanoparticles, simple to be tuned by
HAuCl4 concentration.
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Physicochemical Characterization of
Gold Nanoparticles Decorated With
AGMA1-SH and/or Trastuzumab
Direct TEM observation of Au@PT complexes showed that
all colloidal solutions contained monodispersed and spherical-
shaped nanoparticles matching their designs (Figure 3A). As
reported in the experimental section, the gold nanoparticle
average diameter was determined by XRPD analyses using
Scherrer equation. All colloidal samples were absorbed on
XC72R carbon (1%Au/C) and the peak at 2θ = 38.5◦, typical
of metallic gold, was considered. A long experimental work
allowed to reach the expected theoretical values for most of
the samples, especially when the polymer and the drug were
both present (Figure 3B). Size evaluation of the whole colloidal
nanosystem (gold – polymer – drug) required DLS technique.
DLS measures the time-dependent fluctuations in the intensity of
scattered light from a suspension of particles undergoing random
Brownian motion. Analysis of these intensity fluctuations allows
the determination of diffusion coefficients, which in turn yield
the particle size through the Stokes-Einstein equation. Table 1
reports the hydrodynamic diameter average and Z-potential for
all samples. Particles size and Z-potential are very important
parameter to evaluate the stability of colloidal system (Sun
et al., 2016). Absolute values of Z-potential above ± 30 mV are
typically considered as an indicator of suspension stability against
aggregation due to charge stabilization (i.e. the electrostatic
repulsive forces are high enough to counteract aggregation)
(Lowry et al., 2016). Meaningfully, Z-potential value can provide
an explanation about the absorption mechanisms of drugs and
biological ligands on nanoparticles surface. Likewise, it can be a
key factor in determining the interaction with the cells. As listed
in Table 1, all the AuNP spheres (with or without AGMA1-SH)
showed a positive Z-potential value. However, some significant
differences were observed. In absence of AGMA1-SH, the
Z-potential values of Au@T nanoparticles decreased dramatically
toward Z-values closed to neutrality when particle size increased,
especially for the 5Au@T nanoparticles, which indicated a very
low stability of the nanosystems. The reason can be attributed
to the absence of the stabilizing effect of AGMA1-SH, that if
present on the surface may impedes nanoparticle aggregation
by steric hindrance to prevent surface interactions between
AuNPs (Gao et al., 2012). After the addition of AGMA1-SH,
the Z-potential value of the differently sized Au@P intensely
increased. The most relevant increase was observed for 5Au@P
(from 0.2 to 33.8 mW), confirming the impact of AGMA1-SH
to prevent nanoparticles aggregation and deposition. After the
Trastuzumab conjugation, a slight and not significant decrease
on Z-values was assessed in 2.5 and 3.5Au@PT suspensions than
2.5 and 5Au@P counterparts (24.2 to 18.4 mV for 2.5Au@PT
and 23.0 to 21 mW for 3.5Au@PT, respectively). With value
higher than 30.0 mW, 5Au@P and 5Au@PT represent the
most stable nanoparticles, underling a possible effect due to
the size of the nanospheres. Numerous strategies explored the
attachment of a targeting ligand (i.e. sugars and peptides)
through S-Au bonds (Bertrand et al., 2014; Doulain et al.,
2015). Although some drawbacks, particular promising are those
exploiting these bonds for the functionalization with molecules
for biosensing, anticancer drug delivery (i.e. antibodies), and
bioimaging (Ghosh et al., 2008; Gautier and Cisnetti, 2012).
Recently, Matos et al. (2018) used an engineered Trastuzumab
presenting an additional free cysteine per light chain, obtaining
a stable and homogeneous gold thiol-linked Thiomab conjugate
with unmodified anticancer activities. Sulfur is a component of
Trastuzumab itself (C6470H10012N1726O2013S42, hence 42 Sulfur
atoms per molecule). Hence, it is reasonable to speculate that its
free thiol groups may contribute on the stability enhancement
of AGMA1-SH-coated gold nanoparticles interacting directly
with the gold surface. The UV-vis spectra displayed a plasmon
resonance band (PRB) in the strict range 498–504 nm for the
smallest samples (2.5Au@PT, 2.5Au@P, and 2.5Au@T), 508–
515 nm for the intermediate-sized samples (3.5Au@PT, 3.5Au@P,
and 3.5Au@T) and 517–525 nm for the largest ones (5Au@PT,
5Au@P, and 5Au@T) (Figure 3C and Supplementary Figure S2).
The location of PRB peak strongly depends on the size of the
metal nanoparticles, as well as on the surrounding medium and
its dielectric constant. In particular, the larger the nanoparticles,
the higher the wavelength. Hence, the detected PRB values are
coherent with the expected theoretical trend (Figure 3C).
In addition to the physicochemical characteristics of
all nanoparticle’s formulations tested, the efficiency of the
conjugation reaction was also determined (Table 2 and
TABLE 1 | Size distribution of hydrodynamic diameters (dh) and Z-potential as
determined by DLS.
Number size
Sample distribution Z potential
[nm] [mV]
AGMA1SH 1.3 (97.6%) ± 0.2;
3.2 (2.4%) ± 0.7
Trastuzumab 9.3 (100%) ± 2
2.5Au@PT 6.0 (100%) ± 1 18.4 (85.1%) ± 2.7; 3.2 (12.9%) ± 1.7
3.5Au@PT 9.5 (100%) ± 3 21.0 (86.2%) ± 7.2; 3.8 (13.8%) ± 1.3
5Au@PT 27.0 (100%) ± 6 32.6 (100%) ± 9.4
2.5Au@P 5.4 (100%) ± 1 24.2 (69.6%) ± 2.6; 6.7 (27.3%) ± 3.3
3.5Au@P 14.8 (100%) ± 5 23.0 (73.3%) ± 3.0; −2.8 (26.7%) ± 1.6
5Au@P 22.1 (100%) ± 7 33.8 (100%) ± 7.6
2.5Au@T 19.9 (100%) ± 6 7.4 (100%) ± 3.5
3.5Au@T 63.1 (100%) ± 21 13.6 (100%) ± 7.5
5Au@T 77.0 (100%) ± 29 0.2 (100%) ± 0.1
TABLE 2 | Conjugation efficiency of AGMA1-SH-AuNPs.
Samples Conjugation efficiency%a µg of Trastuzumab
per 20 µg of nanoparticlesb
2.5Au@PT 50.2 ± 3.9 10 ± 0.8
3.5Au@PT 60.0 ± 6.3 11.9 ± 1.3
5Au@PT 69.4 ± 7.8 13.9 ± 1.6
aConjugation efficiency% = (1 − ([Trastuzumab in the supernatant]/[Trastuzumab
added in the conjugation reaction])) × 100. bµg of Trastuzumab per 20 µg
nanoparticles = Trastuzumab added in the conjugation reaction − Trastuzumab
in the supernatant.
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Supplementary Table S2). Trastuzumab was conjugated to
the Au@P with an efficiency of ∼50–70%. In general, the
percentage of conjugation efficiency augmented by increasing
the gold nanoparticles sizes. It was approximately of 50.2± 3.9%
for 2.5Au@PT, 60.0 ± 6.3% for 3.5Au@PT and 69.4 ± 7.8%
for 5Au@PT, respectively, denoting that the size of gold
nanoparticles intensely impacts the binding with the targeting
molecules. The relative amount of T (µg) per nanoparticles (µg)
are also reported (Table 2). Beyond to visualize Trastuzumab on
the nanoparticles as spots on the nitrocellulose membrane, dot
blot assay confirmed the indirect values obtained by BCA analysis
(Supplementary Table S3 and Supplementary Figure S3).
Size-related effect was also recorded in the Trastuzumab-
functionalized nanoparticles without AGMA1-SH. It is
worth noting that, in all these nanoparticles, the amount of
Trastuzumab per nanoparticles was lower than AGMA1-
SH-coated gold nanoparticles (Supplementary Table S2).
Gao et al. (2012) documented that a thiol-ending polyethylene
glycol (PEG-SH), significantly improved to colloidal stability
of gold nanoparticles in aqueous solution, facilitating their
conjugation with epidermal growth factor receptor antibodies.
Hence, presumably the AGMA1-SH presence, stabilizing the
gold nanoparticles, may be crucial for the establishment of a
successful interaction with the antibody (Gao et al., 2012). In
nanobiotechnology applications, curvature of nanoparticles has
a significant effect on protein structure and activities, although
little is exactly known about molecular level mechanism.
Likewise, hydration layer above the nanoparticles surface,
the ionic strength of buffer solution and stabilizing polymers
concentration can be critical factors for protein interaction
with nanoparticles (Iijima and Kamiya, 2009; Kushida et al.,
2014; Yu and Zhou, 2016; Lin et al., 2017). Kushida et al.
(2014) showed that the interaction of the coagulation proteins
with silica nanoparticles decreases with the decreasing NP size
FIGURE 3 | Characterization of Trastuzumab-conjugated gold nanoparticles with different sizes. (A) TEM images of 2.5 (a), 3.5 (b), and 5 (c) nm core diameter
Au@PT nanoparticles (Scale bar = 200 nm), (B) XRPD, (C) UV-vis absorbance spectra (circle at 280 nm indicates the Trastuzumab peak), and (D) circular dichroism
measurements of each Trastuzumab-conjugated gold nanoparticles families as function of core size.
TABLE 3 | Hydrodynamic diameter (nm) of Trastuzumab-AGMA1-SH-gold nanoparticles dispersed in complete cell culture media at two different time points.
2.5Au@PT 3.5Au@PT 5Au@PT
Media 0 (h) 4 (h) 0 (h) 4 (h) 0 (h) 4 (h)
McCoy’s + 10% FBS 7.3 ± 1 17.5 ± 2 10.9 ± 1 18.7 ± 1 20.1 ± 1 27.0 ± 1
MEM eagles + 10% FBS 9.1 ± 1 16.5 ± 2 8.3 ± 3 16.6 ± 1 23.3 ± 1 32.3 ± 1
DMEM + 10% BCS 9.7 ± 2 21.5 ± 2 13.0 ± 1 30.9 ± 4 21.9 ± 1 23.7 ± 3
Mean value and standard deviation of three measurements per condition are reported.
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(higher curvature). Vertegel et al. (2004) observed a greater
loss of lysozyme conformation adsorbed onto larger silica
nanoparticles under otherwise similar conditions. About the
gold nanoparticles, the effects of curvature on ligand interaction
remains a complicate issue (Villarreal et al., 2017). Villarreal et al.
(2017) CD spectroscopy method is commonly used to determine
protein structure and its interaction with other molecules. CD
spectroscopy confirmed the Trastuzumab conjugation to the gold
nanoparticles (Figure 3D and Supplementary Figure S4), but
also suggested a correlation between Trastuzumab-conjugated
secondary structure maintenance and the particle hydrodynamic
radius (R). Consistently with literature findings (Jiang et al.,
2005, 2008; Worrall et al., 2006; Saptarshi et al., 2013), the
correct folding increased with R growing from 2.5Au@PT to
5Au@PT (Figure 3D). Only the largest nanoparticles (5Au@PT)
displayed CD spectra superimposable to the unconjugated
antibody, indicating that the nanoparticles are a highly
efficient and selective tool for HER-2 receptor. Previous studies
hypothesized that the higher surface curvature of smaller
nanoparticles may restrict the relative orientation between
antibodies, resulting in a certain degree of conformational
rigidity, that while blocking the correct protein folding, it
impaired their docking receptor surface (Jiang et al., 2008).
By contrast, for conjugates built on larger sizes, the antibody,
once absorbed on nanoparticles surface, extended itself into the
surrounding medium in a conformation allegedly better suited
to interact with its receptors (Ghitescu and Bendayan, 1990;
Jiang et al., 2008; Saptarshi et al., 2013). Concerning the in vitro
release of Trastuzumab, each type of Au@PT presented a low
released amount in MilliQ water up to 15 days of investigation
(5.3± 0.7%, 4.4± 0.5%, and 3.5± 0.6% for 2.5, 3.5, and 5Au@PT,
respectively) (Supplementary Figure S5). Interestingly, analyses
up to 12 months showed that 5Au@PT complex was the
most stable of storage at refrigerated conditions, without any
aggregate’s formation and with an approximately release of
20 ± 0.3%. By contrast, both 2.5 and 3.5Au@PT displayed a
tendency to precipitate after few months from their synthesis.
Challenging and crucial aspect of nanoparticles characterization
is the measurement of their stability under condition resembling
in vitro or in vivo environment. Numerous studies revealed
that the proteins, salts, and antibiotics present in the different
culture media can interact with AuNPs, determining radical
changes in their size by forming aggregates and reducing their
stability (Moore et al., 2015). Notably, all these components
can confer the particles with a new biological identity and then
dramatically alter their interaction with the cells (Gebauer et al.,
2012). Therefore, it has been becoming increasingly evident that
the nanoparticles toxicity and activity assessed in vitro entails
the mixing nanoparticles of interest with the biological media
for enhancing the comprehension of their interaction with the
biological systems. Hence, to mimic the cell bioenvironment
prior to cells treatment, freshly synthesized batches of Au@PT
nanoparticles were re-suspended in the cell culture media
(containing 10% of serum) proper for each cell lines used for
biological investigation. Hydrodynamic changes were assessed
by DLS analysis at 37◦C after 4 h of incubation. As shown in
Table 3 after serum incubation, the hydrodynamic diameter
of the three types of Au@PTs (in particular for the smaller
ones) increased suggesting the serum proteins adsorption on
nanoparticle surface, that forming a “corona.” Although with
discrepancies in the results, numerous studies on different
types of nanoparticles and on various cell lines highlighted
the significance of protein corona (Hajipour et al., 2015). They
profoundly influence the aggregation of nanoparticles and their
cellular uptake (Dominguez-Medina et al., 2016). Also, it has
been demonstrated that the protein corona composition affects
the internalization of gold nanoparticle coated with different
polymers (Walkey et al., 2014). Recently, it was found that the
“stealth effect” of poly(ethylene glycol) may be explained by the
presence of specific proteins in their protein corona (Schöttler
et al., 2016). As summarized by Moore et al. (2015) the type of
basal medium can dictate the size and stability of nanoparticles.
Results from Strojan et al. (2017) demonstrated that the medium
in which silica nanoparticles were dispersed, had significantly
affected nanoparticles protein corona composition, suggesting
an important implication on nanoparticles potential biological
effects. Ji et al. (2010) have found that titanium dioxide (TiO2)
nanoparticles increased their hydrodynamic in the presence
of cell culture media without serum. By contrast, the addition
of bovine serum protein stabilized nanoparticles, as there was
only a little change in size following the addition of proteins
(Spadavecchia et al., 2016). Moreover, as previously reviewed,
different surface modifications (i.e. by using biocompatible
polymers coating) can be used for lessening the protein corona
formation then improving the stability of nanoparticles in liquid
media (Iijima and Kamiya, 2009). Based on and in agreement
with literature findings (Colombo et al., 2016), we inferred
that the small increase observed on 5Au@PT nanoparticle size,
in all complete media tested, might due to the higher surface
functionalization with T, which decreased the extent of serum
protein adsorption. By contrast, the lower amount of antibody
per nanoparticle on 2.5Au@PT and 3.5Au@PT may favor protein
absorption then resulting in an increase of hydrodynamic
diameter. Overall, protein adsorption may be hindered by the
functionalization of gold nanoparticles with AGMA1-SH and
Trastuzumab, but it cannot be totally inhibited, and a certain
amount of serum proteins do adsorb on the NP surfaces,
irrespective to the presence of polymers coating, justifying then
the small increase of the hydrodynamic size.
It is worth emphasizing that the NPs characterization in
standard conditions for the in vitro biological experiments, i.e.
in serum-containing cell culture medium, is still a questioned
issue. Indeed, additional determining factors can regulate the
nanoparticles amount reaching the cell monolayer and the type
of interaction with cells. Cell types and its protein component,
including the protein secreted by cells, contribute to affect the
deposition of the nanoparticles in the cell-well (Halamoda-
Kenzaoui et al., 2015). Recently, it was observed that nanoparticle
administration method in vitro cell culture could alter particle-
cell interaction (i.e. cellular adsorption and uptake) (Moore et al.,
2019). All the factors make hard to envisage the exact behavior
of the nanoparticles once in contact with the cells and should
to be taken in account during the biological experiments. Whilst
bearing in mind that accurate experiments are required, overall
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characterization proved the efficacy of the use of AGMA1-SH to
produce stable gold nanoparticles. Consequently, their anticancer
activities were subsequent evaluated by in vitro cell models as
follows described.
In vitro Cytotoxicity and Uptake:
Evaluation in Breast Cancer and
No-Neoplastic Cell Lines
In vitro and in vivo successful achievements employing
delivery synthetic nanoplatforms need targeting molecules
to recognize tumor cells specifically, without affecting the
surrounding healthy cells.
Aiming to assess the activities of Au@P functionalized with
Trastuzumab, SKBR-3, human breast cancer cell line was selected
as target cell model. This cell line overexpresses HER2, itself
the target of Trastuzumab, and has been used extensively as
an in vitro model for evaluating the anticancer targeting of
nanoparticles as tool to enhance the selectivity and specificity
of therapies against cancer cells (Kim et al., 2011; Martínez-
Jothar et al., 2019; Niza et al., 2019). Moreover, to confirm
the selective effect of Au@PT toward the HER2-receptor, others
two cell lines were included for comparative analysis: MCF-7,
a human breast cancer expressing low HER-2 as control, and
the murine fibroblasts cell line, NIH-3T3, as health cell model.
Both are commonly used in experimental studies for assessing
the selectivity of anticancer treatments and the nanomaterials
toxicity (Xu et al., 2005; Holliday and Speirs, 2011; Shirshahi
et al., 2013; Merli et al., 2018; Cruz and Kayser, 2019). All
in vitro experiments were conducted treating all cell types
(1 × 104 viable cells/well) with increasing concentrations (from
0 to 2 µg/mL) of each Au@PT size and free-Trastuzumab. The
concentration range was fixed by determining the “no toxic”
dose by incubating the same number of cells with increasing
concentrations of the unfunctionalized Au@P counterparts
(Supplementary Figure S6). A low cytotoxicity was observed
up to 2 µg/mL, then the concentration range upper limit
was set at this value. As reported in Table 2, 2 µg/mL of
2.5Au@PT, 3.5Au@PT, and 5Au@PT contain approximately 1–
1.4 µg of Trastuzumab, which was the concentration within
the effective doses against breast cancer cells (Suarez et al.,
2013). 2.5Au@PT, 3.5Au@PT, and 5Au@PT cytotoxicity was
tested by measuring cell viability using MTT after incubation
with Au@PT. 2.5Au@PT and 5Au@PT were particularly effective
in impairing the SKBR-3 viability, whereas they had low or
no toxicity on MCF-7 and NIH-3T3 respectively (Figure 4A).
Interestingly, cells exposed to Au@PT underwent viability
decrease after 3 days of incubation (around 50 and 20% with
5Au@PT and 2.5Au@PT respectively). It could be argued that
the difference in cells response is due to the changes observed
in the secondary structure of the antibody, which was able to
affect the binding capacity of Trastuzumab-AuNPs with HER-
2 receptors. 3.5Au@PT was comparable to that of 2.5Au@PT
treated cells, nearby 25% at 2 µg/mL (data not shown). Targeting
molecule may reduce their targeting capacity and activities
as protein corona adsorption (Mirshafiee et al., 2013). Also
surface rigidity, ligand density affects nanoparticles effect on cell
(Gong et al., 2015). Consequentially, it is conceivable that lower
activity detected after the treatment with 2.5Au@PT, the ones
showing the highest increase of hydrodynamic size following
the incubation with the complete cell media, may be related to
protein corona absorption. However, other explanations cannot
be excluded. Pan et al. (2007) have demonstrated that the
cytotoxicity of modified gold nanoparticles is dependent on
the size and not on a particular ligand attached to them. In
addition, some researchers showed that because metallic, these
nanoparticles have an effect on cell membrane integrity, and their
size and charge both affect significantly cell viability (Woz´niak
et al., 2017). Similarly, cellular uptake of gold nanoparticles was
influenced by many factors including size, charge, coating, shape,
incubation time and cell types (Dreaden et al., 2012; Panariti
et al., 2012; Yue et al., 2017). Chithrani et al. (2006) observed
that size and shape strongly influenced cellular uptake of citric
acid ligand-modified Au nanospheres, and others reported a clear
interrelationship between nanoparticles surface functionality
an uptake (Jiang et al., 2015). Meanwhile, the adhesion of
nanoparticles onto cell membrane can be reduced because of
protein corona formation around nanoparticles surfaces, which
in turn inhibit their cellular uptake. As reported by Cheng
et al. (2015) protein from serum, modulating biomolecular
corona profile, changed the AuNPs internalization in a size-
and cell type-dependent manner. Aiming to explore the size
contribution in Au@PT uptaking, the succeeding experiments
were performed using nanoparticles differing for about fourfold
in hydrodynamic radius, 2.5Au@PT and 5Au@PT. Others have
previously underlined that an equilibrium between multivalent
crosslinking of membrane receptors and membrane wrapping
involved in receptor-mediated endocytosis exists (Jiang et al.,
2008; Yue et al., 2017). Jiang et al. (2008) showed that
extremely small (2 nm) or large Trastuzumab-conjugated
nanoparticles (>50 nm) would both produce an inefficient
uptake. Aoyama et al. (2003) and Osaki et al. (2004) investigated
size effects and receptor activation, concluding that receptor-
mediated endocytosis is firmly size-dependent with an optimal
size equal to ≈25 nm. Others reported a theoretical model
based on size and receptor-mediated endocytosis that gives
an optimal radius ≈27–30 nm for spherical particles (Gao
et al., 2005). Besides, Wang et al. (2010) using a 3D image
process identified the AuNPs distribution, revealing that the
optimal size is 45 nm for cells uptake. The results here
described seem to show a broader agreement with previous
experimental observations. Indeed, as compared to 2.5Au@PT
(dh ∼ 6 nm), a significant enhancement in the uptake of
5Au@PT (dh ∼ 22 nm) was detected in HER-2 overexpressing
human breast cancer SKBR-3 cells (Figure 4B). Nonetheless,
the internalization of both 2.5Au@PT and 5Au@PT was highly
dependent on time (Figure 4B). Large nanoparticles aggregates
are not suitable for cellular interaction and uptakes. Using SEM-
BSE mode, it was easily appreciated smaller 5Au@PT cluster
coating homogenously SKBR-3 cells surface, whereas a closely
2.5Au@PT were packed into bigger aggregates (Supplementary
Figure S7), suggesting the difficult capture of the latter by
cells. In addition, uptaking studies using unconjugated-Au@P
confirmed the role played by the size, with the most efficient
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 12 March 2020 | Volume 8 | Article 132
fbioe-08-00132 March 2, 2020 Time: 20:46 # 13
Bloise et al. Breast Cancer-Targeting Small AuNPs
uptake occurring with the largest nanoparticles (5Au@P; dh ∼
22 nm) (Supplementary Figure S8).
The accumulation of Au@P and Au@PT inside the cells could
be regulated also by the exocytosis process. It was found that Au
NPs were exocytosed in a linear manner in size, with smaller
AuNPs exhibiting a faster exocytosis rate and percent (after
8 h of incubation, 4 nm-AuNPs were exocytosed while > 90%
of 74 nm remains into the cells) (Chithrani and Chan, 2007).
Equally, the thermodynamic process could be the driving force
for wrapping. In general, smaller particles must be clustered
together to create enough driving for uptake, showing an
uptake amount smaller than 50 nm AuNPs (Gong et al., 2015).
Recently, Cruz E and Kayser V have found that Trastuzumab-
attachment increased nanoparticles cellular uptake in HER2
amplified cell lines selectively (Cruz and Kayser, 2019). Although
higher uptake is required in delivery applications, internalization
must be specific to the targeted tumor cells. In agreement, the
observation that Au@PT internalization was higher in HER2
overexpressing cell line (SKBR-3) than in both MCF-7 and NIH-
3T3, it was a further evidence that cellular uptake increased
through the HER2 receptor crosslinking Trastuzumab-activated
(Figure 4B). Likely, the low percentage of uptakes detected
in MCF-7 and NIH-3T3 was due to passive internalization
(Figure 4B) (Zhao and Stenzel, 2018). Later, in line with
previous studies(van der Meel et al., 2012; Martínez-Jothar et al.,
2019), SKBR-3 cell line showed a significantly increased uptake
for Trastuzumab-conjugated AuNPs as compared to non-
targeted nanoparticles (50% vs. 10%, respectively after 3 days
of incubation); these data further proved that the uptake of
antibody-targeted nanocarriers is truly mediated by specific
ligand-receptor interactions.
HER Targeting: Evaluation of
Morphology, Viability and Intracellular
Changes After Au@PT Treatment
The correct binding of a ligand molecule with cell surface
receptors intimately controls the cell function and fate. Many
works showed that the physical parameters of nanoparticles
(i.e. size) strongly affect ligand binding and the subsequent
activation of its membrane receptors (Chithrani et al., 2006;
Brzóska et al., 2018). In line with quantitative results, FDA assays
showed the highest number of death cells (red signal) in cultures
exposed with 5Au@PT suspension (Figure 5A). SEM images
clearly highlighted this important difference, displaying more
spherical cells in shape with noticeable abnormal morphology
in 5Au@PT-treated samples in comparison with control, free
Trastuzumab or 2.5Au@PT (Figure 5A). The binding of
FIGURE 4 | Cytotoxicity and internalization of Trastuzumab-conjugated gold nanoparticles differently sized. (A) Dose- and time-dependence cell viability of different
cell lines cultured with free Trastuzumab, 2.5Au@PT and 5@AuPT. SKBR-3 (e,f) and MCF-7 cells (c,d) were incubated with 2.5Au@PT or 5Au@PT suspensions with
concentration in the range of 0–2 µg/mL. Similarly, the experiment was performed in NIH-3T3 fibroblasts cell line (a,b) as negative control. After 1 and 3 days of
incubation, cell viability was expressed as percentage of viability determined in the absence of nanoparticles (set at 100%). (B) Uptake efficiency of 2.5Au@PT and
5Au@PT (2 µg/mL) after 1 and 3 days of incubation were determined by ICP-MS in all the indicated cell lines (a, NIH-3T3; b, MCF-7; c, SKBR-3) and calculated as
described in Experimental Section (mean values ± standard deviations; **p < 0.01 and ***p < 0.001).
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FIGURE 5 | (A) Cell morphology assessed by scanning electron microscopy in ctrl (a), with Trastuzumab (b), 2.5Au@PT (c) and 5Au@PT (d), respectively, after
3 days of incubation. Scale bars = 100 µm and mag: 1000×. After 3 days of culture, all experimental groups [ctr (e), T free (f), 2.5Au@PT (g), and 5Au@PT (h)] were
treated with fluorescein diacetate (green cells alive) and propidium iodide (red cells dead) 20× magnification, the scale bar represents 50 µm. (B) Western blotting
analysis of survival (a,b), proliferative (a,c), pro (d,e), and anti-apoptotic (d,f) proteins extracted from SKBR-3 after 24 h incubation with the indicated treatments.
The activation level of AKT or ERK is presented as a ratio between the phosphorylated and total AKT or ERK protein after normalization to β-actin housekeeping
protein signal. Bar graphs show BAX and BCL-XL expression level obtained normalizing β-actin housekeeping protein signal. Statistical significance values are
indicated as ***p < 0.001, **p < 0.01, and *p < 0.05.
the ligand to its surface receptors allows the formation of
multivalent HER-crosslinking surface ErbB2 receptors, affecting
intracellular signaling, consequently inhibiting downstream
pathways involved in cell survival, proliferation, and metastasis
(Klapper et al., 2000).
The strategy of combining the properties of AuNPs with anti-
cancer molecules could be the future of cancer nanomedicine
(Sun et al., 2018). Chattopadhyay et al. (2010) showed that
Trastuzumab-PEG-AuNPs (30 nm) in combination with
300 kVp X-rays enhanced DNA double strand breaks (DSBs) in
SKBR-3 cells. Mechanistic studies performed by Vemuri et al.
(2019) revealed that the functionalization of naturally derived
phytochemicals, such as Quercetin and Paclitaxel, to AuNPs were
significantly effective in inhibiting cell proliferation, apoptosis,
angiogenesis, colony formation and spheroid formation.
AuNPs principally trigger apoptosis through intrinsic pathways,
including mitochondria- and ER-related pathways. Green
synthesized of AuNPs (10 – 42 nm) can induce the apoptosis
activating the caspase-3 and 9 in human cervical cancer cells
(Baharara et al., 2016) and the citrate-coated AuNPs (8 nm)
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promoted apoptosis eliciting BAX translocation and cytochrome
c release in human liver (HL7702) cells (Gao et al., 2011). In
agreement with literature findings (Sun et al., 2018; Vemuri
et al., 2019), Au@PT cytotoxic effects elicited significant changes
in survival and proliferation (AKT/PI3K and ERK pathways,
respectively) as well as apoptotic process (pro-apoptotic BAX,
anti-apoptotic BCL-xL, respectively) (Figure 5B). AKT and ERK
activation levels were significantly reduced in the treatment with
2.5Au@PT and 5Au@PT than with control (Figures 5Ba–c), with
a slight decrease after the incubation with 5Au@PT. Additionally,
both 2.5Au@PT and 5Au@PT treatments led to a substantial
increase in the expression of BAX with concomitant decrease
in expression of BCL-xL in comparison with free Trastuzumab
and control (Figures 5Bd–f). As mentioned, the most marked
changes were observed after 5Au@PT incubation, still proving
the size-effect dependence. Overall, the results showed that
Trastuzumab-AGMA1-SH-gold AuNPs conjugates retain great
antimitotic and anti-apoptotic effectiveness after the conjugation
to Au@PT, which could improve the cancer therapeutic effects of
Trastuzumab itself.
HER-2 Targeting: Evaluation of
Internalization by Confocal Laser and
Transmission Electron Microscopies
As a drug delivery platform, an efficient cell uptake is important
to ensure sufficient therapeutic outcomes (Carnovale et al.,
2016). Some studies suggest that Trastuzumab can induce
a rapid internalization of HER-2 (Rubin and Yarden, 2001;
Chattopadhyay et al., 2010; Han et al., 2014), a mechanism
that could facilitate 5Au@PT uptaking by SKBR-3 cells. Co-
localization of HER-2 and gold nanoparticles were then studied
(Figure 6). In cells treated with free Trastuzumab, the antibody
staining (in green) was predominant in cell membrane because
of its interaction with HER-2 receptors (Figures 6Ab,c).
On the other hand, cancer cells incubated with 5Au@PT
exhibited a reduced Trastuzumab staining at the cell membrane
(Figures 6Ad,e) but increased inside the cells and co-localized
with 5Au@PTs as revealed by the scattering signals of gold (in
red) (Figures 6Ad,e).
These data, besides proving the powerful and selective
ability of Trastuzumab to promote the transport of 5Au@PT
into HER-2 overexpressing cells, also suggest that receptors
undergo endocytosis process when bound to Au@PT of a
specific size range.
Transmission electron microscopy provides an excellent tool
for in-depth biological sample analysis at the cellular and
organ level. In the present work, it confirmed SKBR-3 cellular
internalization of 5Au@PTs (Figure 6B). In (c) at higher
magnification, the distribution of the NPs in close proximity of
the vesicle’s membrane seems to evidence the binding between
the drug and its receptor: a cluster of 5Au@PT was approaching
the cell membrane (d) and was trapped inside vesicles of
ranging sizes (e). The electron dense material appears to have
a low resolution due to the silver enhancement procedure.
However, a series of control experiments in absence of silver,
osmium, uranyl and lead ruled out the possibility of artifacts
as shown in Supplementary Figure S9. Generally, AuNPs
were localized within early endosomes and lysosomes (Boyoglu
et al., 2013; Xie et al., 2017). Therefore, it is presumable the
vesicles structures visualized by TEM were the result of the
FIGURE 6 | Internalization of 5Au@PT in breast cancer target cells, SKBR-3. (A) CLSM images of cancer cells incubated for 3 days in absence of 5Au@PT and
Trastuzumab (a), with free Trastuzumab (b,c), and 5Au@PT (d,e). Both Au@PTs were visualized in reflection bands after the excitation at 545 nm and stained in red
false color. Trastuzumab was visualized by anti-human secondary antibody-488 Alexa Fluor. Nuclei were stained with Hoechst 33342 (blue). Scale bar: 20 µm. (B)
TEM samples stained with uranyl and lead for cell morphology: (a) ctrl cells; (b) cells treated with 5Au@PT; uptake of large clusters inside vesicles is clearly visible
after silver enhancement; (c) detail of a cell vesicle containing 5Au@PT; (d,e) high magnification of 5Au@PT putative uptake nearby the cell membrane; scale bars:
2 µm, 2 µm, 500 nm, 500 nm, and 500 nm respectively.
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FIGURE 7 | Cellular uptake mechanism of 5Au@PT quantified with ICP-MS (A) and observed by CLSM (B). In both experiments, uptakes of 5Au@PT were analyzed
in presence of specific endocytosis inhibitors as described in Experimental Section (2.5 mM Amiloride; 2.5 µg/mL Chlorpromazine; 100 µM Indomethacin). (A)
ICP-MS data are expressed as nanoparticles reduction (%). Statistical significance values are indicated as ***p < 0.001, **p < 0.01. (B) CLSM-DIC (differential
interference contrast) mode of cells untreated (a), exposed to 5Au@PT (b), and incubated with different endocytosis inhibitors (c, 2.5 mM amiloride; d, 2.5 mg/mL
chlorpromazine; e, 100 mM indomethacin) for 1 h before the incubation with 5Au@PT for 24 h. Orthogonal view of images stacks is shown. Scattering of Au in red
(false color) nuclei in blue. The focus of cells was adjusted using the differential inference contrast as a reference.
endosome/lysosome trafficking induced by Trastuzumab binding
to its membrane receptor. Some of these structures may be also
autophagosome. Previously, it was observed gold nanoparticles
induces autophagosome accumulation in accordance with size-
dependent nanoparticle uptake and lysosome impairment (Ma
et al., 2011). A high-resolution technique may help to clarify
the full pathway of Au@PT intake and leading to a precise
subcellular localization.
HER-2 Targeting: Molecular Mechanisms
Underlying the 5Au@PT Capture
In conclusion, to underscore the sensitive endocytic route
responsible for 5Au@PT internalization by target cells, three
different endocytosis pathways inhibitors were employed
(Figure 7): amiloride for micropinocytosis inhibition,
chloropromazine for clathrin-mediated endocytosis (receptor
dependent mechanism) and indomethacin for caveolae-mediated
endocytosis inhibition. The uptake of 5Au@PT was dramatically
affected by chloropromazine treatment (around 50% of
reduction), whereas the other two inhibitors did not substantially
modify the delivery into the cells (Figure 7A). Cross-section
analysis confirmed the aforementioned results, revealing
a strong scattering distribution along the cellular surfaces
due to inhibition treatment (Figure 7B). Receptor-mediated
clathrin carries out the uptake of specific macromolecules
(ligands) or ligand-coated NPs following their binding to
receptors on the surface of cell membrane, promoting the
invagination of the plasma membrane to form area with a
higher receptor concentration (Zhao and Stenzel, 2018).This
type of mechanism has been widely used strategy for the
drug delivery by nanocarriers (i.e. nanogel, liposomes).
Saporin-loaded nanobody-targeted polymeric nanoparticles
induced HER2 clustering, and promoting its internalization
causes an efficient NPs receptor-mediated endocytosis with
subsequent intracellular delivery of its cytotoxic cargo (saporin)
(Martínez-Jothar et al., 2019). As regard AuNPs, Trastuzumab-
functionalized AuNPs mostly underwent endocytosis in breast
cancer cells largely through a receptor-facilitated mechanism
(Chattopadhyay et al., 2010; Han et al., 2014; Rathinaraj et al.,
2015; Sun et al., 2018). Han et al. (2014) found that quantum
dots-HER bound specifically to SKBR-3 membrane, inducing
their internalization via a receptor-mediated mechanism. In
accordance with the aforementioned findings, the present
results showed that the most probable mechanism for 5Au@PT
nanoparticle endocytosis in breast cancer cells (SKBR-3) was
receptor-dependent, suggesting that the AuNPs-mediated
delivery of monoclonal antibody toward its specific cell
membrane receptor was achieved efficiently.
In summary, the conjugation of the 5Au@Ps with
Trastuzumab allowed their specific binding to HER-2-
overexpressing cells, and through a receptor-mediated
internalization process, may trigger their deposition into
the cytoplasm, where gold nanoparticles, in combination with
free Trastuzumab released into the cells, likely contribute to
breast cancer cell death.
CONCLUSION
The synthesis and the functionalization of gold-nanoparticles
with cancer-specific biomolecules may represent a winner
strategy for a selective and targeted tumor-phototherapy.
Currently, a considerable number of efforts have been taken in
order to obtain gold-nanoparticles by green and safe method.
In this work, extra-small gold nanospheres stabilized with thiol-
functionalized AGMA1 and Trastuzumab were for the first
time synthesized and tested in vitro as nanovectors for breast
cancer targeted drug delivery. The synthetic method followed
an innovative protocol introducing significant advantages
with respect to other routes presently adopted. In primis,
tailoring thiol-functionalized biocompatible PAAs avoided the
use of conventional stabilizers, often cytotoxic, via Au-S soft-
soft interactions, which ensured long-term stability of the
hybrid nanomaterial without any cytotoxicity. Importantly,
sulfur is even a component of Trastuzumab itself. This
represented an intrinsic, powerful tool for further stabilizing
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the composite nanosystem. Moreover, the employment of an
instant reducing reagent (NaBH4) guaranteed homogeneously
sized and tailored ‘on demand’ gold nanoparticles by properly
tuning HAuCl4 concentration. The cytotoxicity and cellular
uptake behaviors have been investigated in no-neoplastic cells
(NIH-3T3) and in two breast cancer cell lines (MCF-7 and
SKBR-3) by MTT assay and inductively coupled plasma mass
spectrometry (ICP-MS) respectively. It was found that 5Au@PT
with the highest hydrodynamic diameter and positive charge
showed much higher cell internalization ability and cytotoxicity
than the smaller ones (2.5Au@PT and 3.5Au@PT). Moreover, the
experimental results against Trastuzumab target cells (SKBR-3)
demonstrated that the cytotoxicity of 5Au@PT was closely related
to pro-apoptotic protein increase, anti-apoptotic components
decrease, survival-proliferation pathways downregulation and
uptaking by cells via the activation of the classical receptor-
mediated endocytosis. This work thus suggests an utmost
importance of size control at the AuNPs when designing
molecular-cancer delivery systems. Indeed, nonetheless the
present method results suitable for AuNPs synthesis, the stability
and conjugation with anticancer molecules depends on particles
size, which affects also the its interaction with cancer cells. AuNPs
unfortunately are not the optimal candidates for photothermal
therapy (PTT) due to their limited absorption in the near infrared
(NIR) region. In accordance with other studies, to overcome
the size dilemma is possible to assemble small AuNPs into
larger structures through controllable interparticle interaction by
using biodegradable AGMA1-SH, with the final aim to enhance
the absorption of NIR light. Overall, this project should offer
important data for particle design improvement and for speeding
up AuNPs application in breast cancer therapy with enhanced
and personalized therapeutic outcomes.
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